Browse News
Filter News
Found 157 articles
-
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
2/13/2024
Aligos Therapeutics, Inc. today announced the appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications and Nikhil Aneja as Vice President, Finance, effective immediately.
-
CohBar Reports Second Quarter 2023 Financial Results
8/14/2023
CohBar, Inc. reported its financial results and highlights for the second quarter ended June 30, 2023.
-
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced MCC and Cutaneous Squamous Cell Carcinoma (cSCC)
6/5/2023
Morphogenesis, Inc. and CohBar, Inc., announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
-
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0
6/5/2023
Morphogenesis, Inc. and CohBar, Inc. (CWBR) ("CohBar"), today announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
-
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30, 2023
5/30/2023
Morphogenesis, Inc. and CohBar, Inc. today announced that Morphogenesis' abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/30/2023
Morphogenesis, Inc. (“Morphogenesis”) and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
-
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
5/23/2023
CohBar, Inc. and Morphogenesis, Inc. today announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
11/8/2022
CohBar, Inc. reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
10/26/2022
CohBar, Inc. announced that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022.
-
CohBar Announces Reverse Stock Split
9/22/2022
CohBar, Inc. today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock.
-
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
CohBar, Inc. (NASDAQ: CWBR), announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
-
CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
8/15/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.
-
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022Company to host conference call and webcast at 5:00 p.m. ET
8/1/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 2022.
-
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
7/12/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company’s Board, effective July 11, 2022.
-
CohBar to Participate at Upcoming Conferences in June 2022
6/7/2022
CohBar, Inc. announced that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Gradalis Appoints Steven Engle as Chief Executive Officer
6/2/2022
Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced that Steven Engle has joined the company as its Chief Executive Officer.
-
Longevity and Anti-senescence Therapy Market Size to Reach $44.2 BN by 2030
5/26/2022
According to QY Research Medical, the longevity and anti-senescence therapy market size is projected to reach US$ 44.2 billion by 2030, growing at a CAGR of 6.4% from 2021 to 2030.
-
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
5/24/2022
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company.
-
CohBar to Present at the H.C. Wainwright Global Investment Conference
5/19/2022
CohBar, Inc. announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.